查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球大肠直肠癌市场评估：依治疗类型、诊断、最终使用者、地区、机会、预测（2017-2031）
市场调查报告书
商品编码
1417601

全球大肠直肠癌市场评估：依治疗类型、诊断、最终使用者、地区、机会、预测（2017-2031）

Colorectal Cancer Market Assessment, By Treatment Type, By Diagnosis, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 223 Pages | 商品交期: 3-5个工作天内

价格

预计2023年全球大肠直肠癌市场规模将达150.6亿美元，2031年将达207.2亿美元，2024-2031年预测期间复合年增长率为4.07%。近年来，由于大肠癌盛行率的增加、医疗技术的进步和意识的提高等综合因素，大肠直肠癌的治疗和诊断市场呈现显着增长。据世界卫生组织称，大肠直肠癌是第三大常见癌症，约占所有癌症的 10%。大肠直肠癌领域的研究和开发的增加正在透过新的和先进的产品推动市场。此外，强大的新药研发管线和政府为根除癌症所做的努力预计将推动全球大肠癌市场的发展。大肠直肠癌盛行率迅速增加是由于基因突变、发炎性肠道疾病、荷尔蒙和生活方式的改变以及饮酒和吸烟造成的。导致大肠直肠癌早期检测和治疗的技术进步正在促进全球大肠直肠癌市场的成长。然而，用于治疗结直肠癌的生物製剂的高昂成本以及公众对结直肠癌缺乏认识给市场参与者带来了挑战。

大肠直肠癌发生率增加

全球大肠直肠癌市场的主要成长动力之一是全球大肠癌发生率的增加。这种增加可归因于多种因素，包括久坐的生活方式、不健康的饮食、污染水平的增加以及人口老化的加剧。随着越来越多的人在城市地区过着久坐的生活，大肠癌的盛行率持续上升，需要改进筛检、诊断和治疗解决方案。医疗保健提供者和製药公司正在大力投资研发，以开发更有效的诊断工具和治疗方法，以解决日益严重的健康问题。

据世界卫生组织称，结肠癌是全球癌症相关死亡的第二大原因。根据美国临床肿瘤学会公布的数据，预计到 2023 年，美国将有 153,020 名成年人被诊断出罹患大肠癌。这个数字包括106,970例结肠癌（男性54,420例，女性52,550例）和46,050例直肠癌（男性27,440例，女性18,610例）。大肠直肠癌是全球第三大最常被诊断的癌症。

癌症筛检体外诊断技术的进展

肿瘤领域医疗技术的不断进步正在推动全球大肠癌市场的发展。PCR、原位杂交和次世代定序等体外诊断方法正在用于癌症诊断并进行最佳化，从而实现更有效的治疗计划和个人化治疗选择。此外，免疫组织化学、微阵列技术和流式细胞仪等诊断方法的突破性进展显着改善了患者的治疗结果并减少了与传统诊断技术相关的错误。

这些进步正在提高大肠直肠癌患者的治疗质量，并随着製药公司推出创新的新疗法，推动市场显着成长。2023年3月，BGI Genomics宣布与斯洛伐克地区公司Zentya合作，在斯洛伐克推出COLOTECTTM 1.0。斯洛伐克现已推出第一个大肠直肠癌粪便 DNA 检测。COLOTECTTM 1.0 使用粪便 DNA，这是一种非侵入性筛检测试，不仅可以检测大肠直肠癌，还可以检测癌前病变。COLOTECTTM 1.0 使用复杂的甲基化特异性 PCR (MSP) 技术来检测患者粪便样本中的大肠直肠癌生物标记。

增加资金和政府努力

政府组织、组织和机构正在透过宣传活动积极促进大肠癌筛检和治疗，推动市场成长。研究经费的增加使得研究范围更加广泛，包括调查大肠直肠癌的原因、开发新的治疗方法以及改进现有的治疗方法。广泛的研究和开发可以在早期检测和更有效的治疗方面取得突破，最终可以挽救生命。

本报告研究分析了全球大肠直肠癌市场，提供市场规模和预测、市场动态、主要参与者趋势和前景等。

目录

第一章研究方法论

第二章 专案范围与定义

第三章 COVID-19对全球大肠直肠癌市场的影响

第 4 章执行摘要

第五章 全球大肠直肠癌市场展望（2017-2031）

  • 市场规模及预测
    • 金钱数额
    • 数量
  • 按治疗类型
    • 手术
    • 放射治疗
    • 化学处理
    • 靶向治疗
    • 免疫疗法
    • 其他治疗
  • 透过诊断
    • 体外诊断测试
    • 成像
    • 切片技术
    • 其他
  • 按最终用户
    • 癌症研究所
    • 医院
    • 门诊中心
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 市场占有率：依公司划分（2023 年）

第六章 全球大肠直肠癌市场前景：按地区划分（2017-2031）

  • 北美
    • 市场规模及预测
    • 按治疗类型
    • 透过诊断
    • 按最终用户
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 南美洲
    • 巴西
    • 阿根廷
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 越南
    • 韩国
    • 印度尼西亚
    • 菲律宾
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合酋长国
    • 南非

第 7 章 市场测绘（2023）

  • 按治疗类型
  • 透过诊断
  • 按最终用户
  • 按地区

第八章 宏观环境与产业结构

  • 供需分析
  • 进出口分析 - 数量和价值
  • 供应/价值链分析
  • PESTEL 分析
  • 波特五力分析

第九章市场动态

  • 增长动力
  • 成长限制因素（问题、限制因素）

第十章 监理框架与创新

  • 临床试验
  • 专利情况
  • 监管审批
  • 创新/新技术

第十一章 主要公司情况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名市场领导者的市场收入分析（2023 年）
  • 併购/合资（如适用）
  • SWOT分析（5家进入市场的公司）
  • 专利分析（如果适用）

第12章价格分析

第十三章案例研究

第十四章 主要公司展望

  • Amgen Inc.
  • Abbott Laboratories
  • Bruker Corporation
  • Epigenomics AG
  • Clinical Genomics Technologies Pvt. Ltd.
  • VolitionRx Limited
  • F. Hoffmann-La Roche Ltd
  • Sanofi S.A
  • Quest Diagnostics Incorporated
  • Merck KGaA

第十五章 战略建议

第十六章 关于我们公司、免责声明

Product Code: MX10895

Global colorectal cancer market size was valued at USD 15.06 billion in 2023, and is expected to reach USD 20.72 billion in 2031, with a CAGR of 4.07% for the forecast period between 2024 and 2031F. The market for colorectal cancer therapies and diagnostics has witnessed substantial growth in recent years, driven by a combination of factors such as the increasing prevalence of colorectal cancer, advancements in medical technology, and growing awareness. According to WHO, colorectal cancer is the third most common cancer, covering about 10% of all cancer cases. Increasing research and development in the field of colorectal cancer is driving the market through new and advanced products. Additionally, a strong pipeline of new drugs and government initiatives to eradicate cancer are anticipated to drive the global colorectal cancer market. The surge in the prevalence of colorectal cancer can be attributed to inherited mutations in genes, inflammatory bowel diseases, hormonal and lifestyle changes, and alcohol and tobacco consumption. Technological advancements that result in early detection and treatment of colorectal cancer are contributing to the growth of the global colorectal cancer market. However, the high cost associated with biologics used for colorectal cancer treatment and the lack of awareness about colorectal cancer among the general population is the challenges for market players to tackle.

Increasing Incidence of Colorectal Cancer

One of the primary factors propelling the growth of global colorectal cancer market is the increase in the incidence of colorectal cancer cases across the globe. This rise can be attributed to various factors, including sedentary lifestyles, unhealthy dietary habits, increasing pollution levels, and the growing geriatric population. As more people lead increasingly urban and desk-bound lives, the prevalence of colorectal cancer continues to climb, necessitating enhanced screening, diagnosis, and treatment solutions. Healthcare providers and pharmaceutical companies invest heavily in research and development to develop more effective diagnostic tools and treatments to address growing health concerns.

As per WHO, colon cancer is the second leading cause of cancer-related deaths worldwide. According to data published by American Society of Clinical Oncology, in 2023, an estimated 153,020 adults in the United States will be diagnosed with colorectal cancer. These numbers include 106,970 new cases of colon cancer (54,420 men and 52,550 women) and 46,050 new cases of rectal cancer (27,440 men and 18,610 women). Worldwide, colorectal cancer is the third most diagnosed cancer.

Advancements in In-Vitro Diagnostic Technologies for Cancer Screening

The continuous advancements of medical technology in the field of oncology have been instrumental in driving the global colorectal cancer market. In-vitro diagnostic methods like PCR, In-situ hybridization, and next-generation sequencing are utilized and optimized for cancer diagnostics, allowing for more effective treatment planning and personalized therapy options. Moreover, breakthroughs in diagnostic methods, such as immunohistochemistry, microarray technique, and flow cytometry are significantly improving patient outcomes and reducing the errors associated with conventional diagnostics techniques.

These advancements are enhancing the quality of care for colorectal cancer patients and driving substantial growth in the market as pharmaceutical companies are launching new and innovative treatments. In March 2023, BGI Genomics announced that COLOTECTTM 1.0 would be introduced in Slovakia in collaboration with the regional business Zentya. One of the country's first fecal DNA tests for colorectal cancer has now been made available. Fecal DNA is used by COLOTECTTM 1.0, a non-invasive screening test, to detect precancerous abnormalities as well as colorectal cancer. It uses multiplex methylation-specific PCR (MSP) technology to detect colorectal cancer biomarkers in fecal samples of patients.

Increasing Funding and Government Initiatives

Government organizations, associations, and agencies are actively promoting the screening and treatment of colorectal cancer through awareness initiatives, thereby fostering market growth. Increased research grants have enabled more extensive research into the causes of colorectal cancer, development of new treatments, and improvement of existing therapies. Extensive research and development can lead to breakthroughs in early detection methods and more effective treatment options, ultimately saving lives.

The government is consistently providing research grants each year for development of novel colorectal cancer therapies. In 2021, National Cancer Institute (United States) invested USD 248 million for colorectal cancer research. As per fact sheet published by The White House, American government invested USD 394.5 million during the 2022-2023, in CDC's cancer initiatives that includes Colorectal Cancer Control Program to increase colorectal cancer screening rates among people aged 45 to 75 years.

Impact of COVID-19

The COVID-19 pandemic had a significant impact on the colorectal cancer market, affecting various aspects of research, diagnosis, treatment, and patient care. During the pandemic, many non-urgent medical procedures, including colorectal cancer screenings, were postponed, or canceled to prioritize COVID-19 patients and reduce the risk of virus transmission. The delay in screenings led to lower identification of cancer cases at more advanced stages, potentially reducing the chances of successful treatment. Many individuals with colorectal cancer or symptoms that could be an indication of the disease were postponed or avoided due to concerns about COVID-19 transmission in healthcare settings. Conclusively, the COVID-19 pandemic had a multifaceted impact on the colorectal cancer market, affecting screening, diagnosis, treatment, and patient care.

Key Players Landscape and Outlook

The landscape of key players in the colorectal cancer market includes a mix of pharmaceutical companies, medical device manufacturers, and diagnostic service providers. These organizations are actively involved in various aspects of colorectal cancer, including research, drug development, diagnostics, and treatment. The colorectal cancer market is highly dynamic, with ongoing research, drug development, and advancements in diagnostic and treatment modalities. These key players are at the forefront of efforts to combat colorectal cancer and improve patient outcomes.

For instance, Takeda and Hutchmed (China) Limited announced in May 2023 about the New Drug Application (NDA) for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, has been granted priority review by the United States Food and Drug Administration (FDA) for the treatment of adult patients with metastatic colorectal cancer that has already received prior treatment.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on Global Colorectal Cancer Market

4. Executive Summary

5. Global Colorectal Cancer Market Outlook, 2017-2031F

  • 5.1 Market Size & Forecast
    • 5.1.1 By Value
    • 5.1.2 By Volume
  • 5.2 By Treatment Type
    • 5.2.1 Surgery
    • 5.2.2 Radiation therapy
    • 5.2.3 Chemotherapy
      • 5.2.3.1 Alkylating Agents
      • 5.2.3.2 Antimetabolites
      • 5.2.3.3 Others
    • 5.2.4 Targeted therapy
    • 5.2.5 Immunotherapy
      • 5.2.5.1 Panitumumab
      • 5.2.5.2 Cetuximab
      • 5.2.5.3 Bevacizumab
      • 5.2.5.4 Others
    • 5.2.6 Other Treatments
  • 5.3 By Diagnosis
    • 5.3.1 In-vitro Diagnostic Testing
      • 5.3.1.1 Polymerase Chain Reaction (PCR)
      • 5.3.1.2 Blood Test
      • 5.3.1.3 In-situ Hybridization (ISH)
      • 5.3.1.4 Immunohistochemistry
      • 5.3.1.5 Next-generation Sequencing (NGS)
      • 5.3.1.6 Microarrays
      • 5.3.1.7 Flow Cytometry
      • 5.3.1.8 Immunoassays
      • 5.3.1.9 Other In-vitro Diagnostic Testing Technologies
    • 5.3.2 Imaging
      • 5.3.2.1 Magnetic Resonance Imaging (MRI)
      • 5.3.2.2 Computed Tomography (CT)
      • 5.3.2.3 Positron Emission Tomography (PET)
      • 5.3.2.4 Mammography
      • 5.3.2.5 Ultrasound
    • 5.3.3 Biopsy Technologies
    • 5.3.4 Others
  • 5.4 By End-user
    • 5.4.1 Cancer Research Institutes
    • 5.4.2 Hospitals
    • 5.4.3 Ambulatory Care Centers
    • 5.4.4 Others
  • 5.5 By Region
    • 5.5.1 North America
    • 5.5.2 Europe
    • 5.5.3 Asia Pacific
    • 5.5.4 South America
    • 5.5.5 Middle East & Africa
  • 5.6 By Company Market Share (%), 2023

6. Global Colorectal Cancer Market Outlook, By Region, 2017-2031F

  • 6.1. North America*
    • 6.1.1. Market Size & Forecast
      • 6.1.1.1. By Value
      • 6.1.1.2. By Volume
    • 6.1.2. By Treatment Type
      • 6.1.2.1. Surgery
      • 6.1.2.2. Radiation therapy
      • 6.1.2.3. Chemotherapy
      • 6.1.2.3.1. Alkylating Agents
      • 6.1.2.3.2. Antimetabolites
      • 6.1.2.3.3. Others
      • 6.1.2.4. Targeted therapy
      • 6.1.2.5. Immunotherapy
      • 6.1.2.5.1. Panitumumab
      • 6.1.2.5.2. Cetuximab
      • 6.1.2.5.3. Bevacizumab
      • 6.1.2.5.4. Others
      • 6.1.2.6. Other Treatments
    • 6.1.3. By Diagnosis
      • 6.1.3.1. In-vitro Diagnostic Testing
      • 6.1.3.1.1. Polymerase Chain Reaction (PCR)
      • 6.1.3.1.2. Blood Test
      • 6.1.3.1.3. In-situ Hybridization (ISH)
      • 6.1.3.1.4. Immunohistochemistry
      • 6.1.3.1.5. Next-generation Sequencing (NGS)
      • 6.1.3.1.6. Microarrays
      • 6.1.3.1.7. Flow Cytometry
      • 6.1.3.1.8. Immunoassays
      • 6.1.3.1.9. Other In-vitro Diagnostic Testing Technologies
      • 6.1.3.2. Imaging
      • 6.1.3.2.1. Magnetic Resonance Imaging (MRI)
      • 6.1.3.2.2. Computed Tomography (CT)
      • 6.1.3.2.3. Positron Emission Tomography (PET)
      • 6.1.3.2.4. Mammography
      • 6.1.3.2.5. Ultrasound
      • 6.1.3.3. Biopsy Technologies
      • 6.1.3.4. Others
    • 6.1.4. By End-user
      • 6.1.4.1. Cancer Research Institutes
      • 6.1.4.2. Hospitals
      • 6.1.4.3. Ambulatory Care Centers
      • 6.1.4.4. Others
    • 6.1.5. United States*
      • 6.1.5.1. Market Size & Forecast
      • 6.1.5.1.1. By Value
      • 6.1.5.1.2. By Volume
      • 6.1.5.2. By Treatment Type
      • 6.1.5.2.1. Surgery
      • 6.1.5.2.2. Radiation therapy
      • 6.1.5.2.3. Chemotherapy
      • 6.1.5.2.3.1. Alkylating Agents
      • 6.1.5.2.3.2. Antimetabolites
      • 6.1.5.2.3.3. Others
      • 6.1.5.2.4. Targeted therapy
      • 6.1.5.2.5. Immunotherapy
      • 6.1.5.2.5.1. Panitumumab
      • 6.1.5.2.5.2. Cetuximab
      • 6.1.5.2.5.3. Bevacizumab
      • 6.1.5.2.5.4. Others
      • 6.1.5.2.6. Other Treatments
      • 6.1.5.3. By Diagnosis
      • 6.1.5.3.1. In-vitro Diagnostic Testing
      • 6.1.5.3.1.1. Polymerase Chain Reaction (PCR)
      • 6.1.5.3.1.2. Blood Test
      • 6.1.5.3.1.3. In-situ Hybridization (ISH)
      • 6.1.5.3.1.4. Immunohistochemistry
      • 6.1.5.3.1.5. Next-generation Sequencing (NGS)
      • 6.1.5.3.1.6. Microarrays
      • 6.1.5.3.1.7. Flow Cytometry
      • 6.1.5.3.1.8. Immunoassays
      • 6.1.5.3.1.9. Other In-vitro Diagnostic Testing Technologies
      • 6.1.5.3.2. Imaging
      • 6.1.5.3.2.1. Magnetic Resonance Imaging (MRI)
      • 6.1.5.3.2.2. Computed Tomography (CT)
      • 6.1.5.3.2.3. Positron Emission Tomography (PET)
      • 6.1.5.3.2.4. Mammography
      • 6.1.5.3.2.5. Ultrasound
      • 6.1.5.3.3. Biopsy Technologies
      • 6.1.5.3.4. Others
      • 6.1.5.4. By End-user
      • 6.1.5.4.1. Hospitals
      • 6.1.5.4.2. Cancer Research Institutes
      • 6.1.5.4.3. Ambulatory Care Centers
      • 6.1.5.4.4. Others
    • 6.1.6. Canada
    • 6.1.7. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1. Germany
    • 6.2.2. France
    • 6.2.3. Italy
    • 6.2.4. United Kingdom
    • 6.2.5. Russia
    • 6.2.6. Netherlands
    • 6.2.7. Spain
    • 6.2.8. Turkey
    • 6.2.9. Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2023

  • 7.1. By Treatment Type
  • 7.2. By Diagnosis
  • 7.3. By End-user
  • 7.4. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis - Volume and Value
  • 8.3. Supply/Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. Amgen Inc.
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. Abbott Laboratories
  • 14.3. Bruker Corporation
  • 14.4. Epigenomics AG
  • 14.5. Clinical Genomics Technologies Pvt. Ltd.
  • 14.6. VolitionRx Limited
  • 14.7. F. Hoffmann-La Roche Ltd
  • 14.8. Sanofi S.A
  • 14.9. Quest Diagnostics Incorporated
  • 14.10. Merck KGaA

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 4. Global Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 5. Global Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global Colorectal Cancer Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 10. North America Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 11. North America Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 16. United States Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 17. United States Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 21. Canada Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 22. Canada Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 26. Mexico Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 27. Mexico Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 31. Europe Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 32. Europe Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 37. Germany Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 38. Germany Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 39. France Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 42. France Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 43. France Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 47. Italy Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 48. Italy Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 52. United Kingdom Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 53. United Kingdom Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 57. Russia Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 58. Russia Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 62. Netherlands Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 63. Netherlands Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 67. Spain Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 68. Spain Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 72. Turkey Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 73. Turkey Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 77. Poland Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 78. Poland Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 82. South America Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 83. South America Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 88. Brazil Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 89. Brazil Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 93. Argentina Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 94. Argentina Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 98. Asia-Pacific Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 99. Asia-Pacific Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 101. India Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 104. India Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 105. India Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 106. China Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 109. China Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 110. China Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 114. Japan Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 115. Japan Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 119. Australia Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 120. Australia Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 124. Vietnam Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 125. Vietnam Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 129. South Korea Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 130. South Korea Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 134. Indonesia Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 135. Indonesia Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 139. Philippines Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 140. Philippines Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 144. Middle East & Africa Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 145. Middle East & Africa Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa Colorectal Cancer Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 150. Saudi Arabia Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 151. Saudi Arabia Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 155. UAE Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 156. UAE Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
  • Figure 160. South Africa Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
  • Figure 161. South Africa Colorectal Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Diagnosis Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023